CEEON EDGE FOLDABLE ULTRAVIOLET LIGHT-ABSORBING POSTERIOR CHAMBER INTRAOCULAR LENS, MODEL 911A
Johnson & Johnson Surgical Vision, Inc. · Decision date Apr 5, 2001
What did the FDA approve?
The FDA database records an approval dated April 5, 2001, for the CEEON EDGE foldable ultraviolet light-absorbing posterior chamber intraocular lens, model 911A, from Johnson & Johnson Surgical Vision, Inc. The device is described as indicated for primary implantation for visual correction of aphakia in persons 60 years of age or older after cataractous lens removal by phacoemulsification, with placement intended in the capsular bag.
This entry is an original PMA approval, not a supplement. The record does not state a supplement type or supplement reason, and no clinical performance data, comparative outcomes, or safety findings are included. The stated purpose is limited to the indication language in the approval statement; the record does not provide independent evidence of effectiveness beyond that reported purpose.
FDA approval order statement
APPROVAL FOR THE CEEON(TM) EDGE FOLDABLE ULTRAVIOLET LIGHT-ABSORBING POSTERIOR CHAMBER INTRAOCULAR LENS - MODEL 911A. THIS DEVICE IS INDICATED FOR PRIMARY IMPLANTATION FOR THE VISUAL CORRECTION OF APHAKIA IN PERSONS 60 YEARS OF AGE OR OLDER IN WHOM A CATARACTOUS LENS HAS BEEN REMOVED BY PHACOEMULSIFICATION. THE LENS IS INTENDED TO BE PLACED IN THE CAPSULAR BAG.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Ophthalmic
- Decision date
- Apr 5, 2001
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P990080
- Regulatory pathway
- Premarket approval application
- Product code
- HQL
- Decision code
- APPR
- Decision date
- Apr 5, 2001
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: intraocular lens.
- Product code
- HQL
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P990080 received
Application receipt date recorded by FDA.
P990080 · FDA decision
APPR
P990080/S067 · Related supplement
TECNIS Foldable Acrylic IOL with OptiEdge, Model ZA9003
Timeline entries are records held by MedtechLedger for P990080. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P990080
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Oct 19, 2026 | FDA |
Explore the linked device profile
Other records with product code HQL
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
FINEVISION HP Trifocal IOLsP240038/S004 | Beaver-Visitec International, Inc. | PMA supplement | Oct 27, 2026 | FDA |
CT LUCIA Intraocular Lenses (IOLs)P100016/S028 | Carl Zeiss Meditec Production, LLC | PMA supplement | Oct 23, 2026 | FDA |
enVista Hydrophobic Acrylic Intraocular LensP910056/S067 | Bausch + Lomb, Inc. | PMA supplement | Oct 23, 2026 | FDA |
| Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Oct 19, 2026 | FDA | |
enVista Hydrophobic Acrylic Intraocular LensP910056/S066 | Bausch + Lomb, Inc. | PMA supplement | Oct 14, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Johnson & Johnson Surgical Vision, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 31 Technology Dr., Suite 200, Irvine, CA, 92618
Sources and methodology
- Original FDA record: P990080
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




